Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Assessment and Therapeutic Activities Reviewed in H2 2017

According to the recently published report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017'; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1313649

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

The report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017' outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Gastrointestinal, Immunology, Oncology, Respiratory, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease and Toxicology which include indications Ocular Hypertension, Glaucoma, Cystic Fibrosis, Resistant Hypertension, Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Nephropathy, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Hypertension, Sickle Cell Disease, Stroke, Systemic Sclerosis (Scleroderma), Tinea pedis (Athlete Foot), Vascular Dementias and Wounds.

Scope

- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/soluble-guanylate-cyclase-sgc-or-ec-4612-pipeline-review-h2-2017-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
Bayer AG
Boehringer Ingelheim GmbH
Ironwood Pharmaceuticals Inc
NicOx SA
SynZyme Technologies LLC
Topadur Pharma AG
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
A-8R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1101042 - Drug Profile
Continued…………..

Enquire About this Report: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1313649

About Market Research Hub:

 Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)

Email: press@marketresearchhub.com

Website: http://www.marketresearchhub.com/

Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.